Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699777 · ClinicalTrials.gov registry record · Phase 1
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
A Phase 1 study of Osteoporosis, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 4
- Study locations
NCT00699777 is a Phase 1 study of Osteoporosis that has completed, run by Warner Chilcott. The registered enrollment target is 96 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00699777, a Phase 1 study of Osteoporosis, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is a randomized, open-label, crossover study to assess the bioequivalence of 1 risedronate 150 mg tablet versus 2 risedronate 75 mg tablets administered as a single oral dose. Approximately 320 subjects will be enrolled from 4 study centers in the U.S.
Conditions Studied
Interventions
- DRUG Risedronate
Study Locations (4)
Florida
- Research Site - Gainesville
- Research Facility - Miramar
Texas
- Research Facility - Austin
- Research Facility - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00699777
The ClinicalTrials.gov registry entry for NCT00699777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (94% lower). The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which Risedronate is the first listed.
NCT00699777 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT00699777 about?
NCT00699777 is a clinical study titled "Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects". This study is a randomized, open-label, crossover study to assess the bioequivalence of 1 risedronate 150 mg tablet versus 2 risedronate 75 mg tablets administered as a single oral dose. Approximately 320 subjects will be enrolled from 4 study centers in the U.S.
What is the current status of trial NCT00699777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2008-01. Estimated completion is 2008-04.
What conditions does trial NCT00699777 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT00699777?
The interventions under investigation include: Risedronate (DRUG).
Who is sponsoring clinical trial NCT00699777?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00699777 being conducted?
This trial has 4 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
COMPLETED · Phase 1
-
Patient- and Physician-Based Osteoporosis Education
COMPLETED · Phase 1
-
Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study
COMPLETED · Phase 1
-
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
COMPLETED · Phase 1
-
A Comparison Study of PF708 and Forteo in Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.